Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

Last updated: September 13, 2024
Sponsor: Frantz Viral Therapeutics, LLC
Overall Status: Active - Recruiting

Phase

2

Condition

Genitourinary Cancer

Lung Cancer

Precancerous Condition

Treatment

Placebo

Artesunate ointment

Clinical Study ID

NCT06206564
ART-AIN IIB-2
  • Ages > 18
  • All Genders

Study Summary

This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult men and women age ≥ 18 years

  • Capable of informed consent

  • Biopsy-confirmed intra-anal high-grade dysplasia (AIN 2, AIN 3, anal HSIL) by HRA.

  • Positive anal human papillomavirus (HPV) test.

  • Women of childbearing potential agree to use birth control for the duration of thestudy.

  • Laboratory values at Screening of:

  1. Serum alanine transaminase (SGPT/ALT) < 5 x upper limit of normal (ULN)

  2. Serum aspartate transaminase (SGOT/AST) < 5 x ULN

  3. Serum Bilirubin (total) < 2.5 x ULN

  4. Serum Creatinine ≤ 1.5 x ULN

  • Electrocardiogram (ECG) with no clinically significant findings as assessed by theInvestigator.

  • Weight ≥ 50kg

Exclusion

Exclusion Criteria:

  • Pregnant and nursing women

  • Diagnosis of low-grade anal dysplasia (AIN 1, LSIL), without the concomitantdiagnosis of anal HSIL, by HRA

  • Concurrent anal, vulvar, cervical, or penile cancer

  • HIV-seropositivity

  • Currently receiving systemic chemotherapy or radiation therapy for another cancer.

  • Patients who are on medical treatment with systemic immunosuppressants or steroids (e.g., active autoimmune disease). Participants using nasal steroid treatments forallergic conditions may participate in the study.

  • Concomitant use of strong UGT (Uridine-diphosphate-glucuronosyltransferase)inhibitors

  • Concomitant use of imiquimod or 5-fluorouracil (5-FU) for the duration of the study

Study Design

Total Participants: 48
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
January 12, 2024
Estimated Completion Date:
December 31, 2025

Study Description

Eligible participants in this study are randomized 2:1 to receive either artesunate or placebo ointment for the treatment of anal HSIL. Both groups receive four 5-day cycles of ointment, at weeks 0, 2, 4, and 6. Participants are followed closely with anoscopy or high resolution anoscopy (HRA) at weeks 8, 18, 30, and 42. After the week 18 HRA visit, participants who have at least partial response will be followed with HRA at week 30.

Participants who are found to be non-responders at week 18 will undergo standard of care ablation.

Participants who are found to have anal HSIL at weeks 30 or 42 will be followed according to standard of care procedures.

Primary Objective: To evaluate the complete and partial histopathologic response to four 5-day cycles of artesunate ointment in adult patients with biopsy-proven HPV-associated intra-anal HSIL (18 weeks).

Secondary Objectives:

Efficacy:

To evaluate the viral clearance after four 5-day cycles of artesunate ointment To evaluate complete and partial intra-anal response To evaluate complete and partial peri-anal response To evaluate persistence of response throughout the study window

Safety:

To evaluate the safety of artesunate ointment for the treatment of intra-anal HSIL.

Connect with a study center

  • Anal Dysplasia Clinic MidWest

    Chicago, Illinois 60614
    United States

    Active - Recruiting

  • Laser Surgery Care

    New York, New York 10011
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.